title: [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
authors.affiliation: Service de dermatologie, CHIC Laënnec, 14, avenue Yves-Thépot, 29000 Quimper, France.
authors.forename: S
authors.initials: S
authors.lastname: Demirtas
authors.affiliation: Centre régional de pharmacovigilance, hôpital La-Cavale-Blanche, CHRU, 29200 Brest, France.
authors.forename: L
authors.initials: L
authors.lastname: El Aridi
authors.affiliation: Service de dermatologie, CHIC Laënnec, 14, avenue Yves-Thépot, 29000 Quimper, France.
authors.forename: M
authors.initials: M
authors.lastname: Acquitter
authors.affiliation: Service de dermatologie, CHIC Laënnec, 14, avenue Yves-Thépot, 29000 Quimper, France.
authors.forename: C
authors.initials: C
authors.lastname: Fleuret
authors.affiliation: Service de dermatologie, CHIC Laënnec, 14, avenue Yves-Thépot, 29000 Quimper, France. Electronic address: p.plantin@ch-cornouaille.fr.
authors.forename: P
authors.initials: P
authors.lastname: Plantin
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab